Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PCSANASDAQ:PTIXNASDAQ:SRNENASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePCSAProcessa Pharmaceuticals$0.30+1.1%$0.27$0.15▼$3.10$3.57M1.361.14 million shs5.39 million shsPTIXProtagenic Therapeutics$3.81-4.8%$3.89$2.35▼$21.00$2.36M0.28552,133 shs252,895 shsSRNESorrento Therapeutics$0.00+30.8%$0.00$0.00▼$0.02$937K1.1383,095 shs15,045 shsWINTWindtree Therapeutics$0.79-5.9%$1.10$0.73▼$737.44$2.89M0.82753,570 shs110,171 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePCSAProcessa Pharmaceuticals+1.00%+24.57%+32.17%-44.77%-82.37%PTIXProtagenic Therapeutics-4.75%-29.05%+24.84%-10.77%-81.47%SRNESorrento Therapeutics+30.77%+6.25%+88.89%+240.00%-84.55%WINTWindtree Therapeutics-5.95%+5.60%-30.09%-75.16%-99.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPCSAProcessa Pharmaceuticals2.464 of 5 stars3.52.00.00.01.81.71.3PTIXProtagenic Therapeutics0.473 of 5 stars0.02.00.00.02.81.70.0SRNESorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWINTWindtree Therapeutics1.5959 of 5 stars3.02.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePCSAProcessa Pharmaceuticals 3.00Buy$6.001,878.89% UpsidePTIXProtagenic Therapeutics 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.0044,203.80% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPCSAProcessa PharmaceuticalsN/AN/AN/AN/A$4.05 per shareN/APTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ASRNESorrento Therapeutics$60.32M0.02N/AN/AN/A∞WINTWindtree TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePCSAProcessa Pharmaceuticals-$11.12M-$3.08N/AN/AN/AN/A-195.21%-163.06%8/12/2025 (Estimated)PTIXProtagenic Therapeutics-$5M-$13.11N/A∞N/AN/A-308.97%-228.73%8/12/2025 (Estimated)SRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/AWINTWindtree Therapeutics-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%N/ALatest SRNE, WINT, PCSA, and PTIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A5/13/2025Q1 2025PTIXProtagenic TherapeuticsN/A-$2.75N/A-$2.75N/AN/A5/8/2025Q1 2025PCSAProcessa Pharmaceuticals-$0.77-$0.30+$0.47-$0.30N/AN/A3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$3.36N/A-$0.24N/AN/A3/20/2025Q4 2024PCSAProcessa Pharmaceuticals-$0.92-$0.74+$0.18-$0.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPCSAProcessa PharmaceuticalsN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPCSAProcessa PharmaceuticalsN/A3.973.97PTIXProtagenic TherapeuticsN/A1.801.80SRNESorrento TherapeuticsN/AN/AN/AWINTWindtree TherapeuticsN/A0.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPCSAProcessa Pharmaceuticals91.93%PTIXProtagenic Therapeutics7.97%SRNESorrento Therapeutics0.02%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipPCSAProcessa Pharmaceuticals9.60%PTIXProtagenic Therapeutics35.00%SRNESorrento Therapeutics2.60%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePCSAProcessa Pharmaceuticals2011.88 million2.84 millionNot OptionablePTIXProtagenic Therapeutics2589,0004.71 millionNot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataWINTWindtree Therapeutics303.66 million11.01 millionNot OptionableSRNE, WINT, PCSA, and PTIX HeadlinesRecent News About These CompaniesShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 110.2%May 30 at 1:27 AM | americanbankingnews.comWINT stock touches 52-week low at $0.75 amid steep annual declineMay 24, 2025 | uk.investing.comWindtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025May 22, 2025 | quiverquant.comWindtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025May 22, 2025 | globenewswire.comWindtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure ConferenceMay 19, 2025 | manilatimes.netWindtree Therapeutics to Present Istaroxime Data at European Society of Cardiology Heart Failure 2025 ConferenceMay 19, 2025 | quiverquant.comWindtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesMay 16, 2025 | finanznachrichten.deWindtree Therapeutics announces resale of 42.17M shares by selling stockholdersMay 16, 2025 | msn.comWindtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure CongressMay 13, 2025 | nasdaq.comWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025May 12, 2025 | globenewswire.comWindtree Therapeutics Unveils U.S. Exclusivity Strategy for IstaroximeMay 10, 2025 | msn.comWindtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic ShockMay 8, 2025 | nasdaq.comWindtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for USMay 6, 2025 | globenewswire.comBiotech Company Jumps Into Houston Multifamily In Quest For Revenue Amid Stock SlideMay 5, 2025 | bisnow.comWhy biotech firm Windtree Therapeutics is buying a 436-unit apartment complexMay 5, 2025 | bizjournals.comWindtree Therapeutics Announces Plans to Acquire Multifamily Residential PropertyMay 5, 2025 | msn.comWindtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline DevelopmentMay 1, 2025 | finance.yahoo.comWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesApril 15, 2025 | markets.businessinsider.comEvofem announces license and supply agreement with Windtree TherapeuticsMarch 27, 2025 | markets.businessinsider.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRNE, WINT, PCSA, and PTIX Company DescriptionsProcessa Pharmaceuticals NASDAQ:PCSA$0.30 +0.00 (+1.07%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.26%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Protagenic Therapeutics NASDAQ:PTIX$3.81 -0.19 (-4.75%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$3.78 -0.03 (-0.79%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Sorrento Therapeutics NASDAQ:SRNE$0.0017 +0.00 (+30.77%) As of 05/29/2025 03:49 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.Windtree Therapeutics NASDAQ:WINT$0.79 -0.05 (-5.94%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.78 -0.02 (-1.90%) As of 05/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
